The standard complaint about peptide influencers is that they exaggerate. That's true and it's boring. Every commercial information ecosystem exaggerates. The more interesting problem is structural: this field punishes the people who are honest about uncertainty, and it does so automatically.
Consider two pieces of content about the same compound.
The first says: "This is the recovery peptide everyone's sleeping on." Clean, confident, shareable, algorithmically rewarded.
The second says: "There's a solid rodent literature here spanning two decades, no completed human trial, and the doses in those studies don't translate the way people assume."
The second is more accurate and more useful. It will lose to the first every time — not because audiences are stupid, but because hedging reads as weakness in a format optimized for confidence, and because the accurate version requires the viewer to hold two ideas at once while the confident version requires nothing.
Nobody's paid to say "we don't know yet"
Look at who funds the conversation. Sellers want compounds to sound effective. Creators want content that performs. Coaches want protocols that sound authoritative. Even critics have an incentive toward theatrical debunking, because "this is fake" performs about as well as "this is miraculous."
The one position with no natural constituency is the calibrated one: promising, early, incompletely studied, worth watching. That sentence sells nothing, debunks nothing, and gets no engagement. It also happens to be the truthful description of most of this field.
The tell is the missing sentence
Here's a practical filter, and it costs nothing to apply.
When someone describes what a peptide does, listen for whether they ever name the model — the species, the trial, the population. "Studies show it helps with recovery" is a claim with the evidentiary layer sanded off. "Rodent studies from one lab reported accelerated tendon healing, and nobody has run this in humans" is the same claim with its actual weight attached.
The first version isn't a lie. It's a claim stripped of the only information that would let you evaluate it — which is arguably worse than a lie, because a lie can be caught.
Anyone who never names the model is either not reading the papers or is choosing to omit the part that makes their claim smaller. Both should cost them your trust.
Our own position, since it's fair to ask
This publication is published by a company that sells research compounds. That's disclosed on every page, and it should absolutely factor into how you read us.
So here's the incentive, stated plainly: we think the honest version wins on a long enough timeline, because readers who understand evidence quality make better decisions and stay. We would rather have an audience that can catch us being wrong than one that can't. That's a commercial bet as much as an editorial one, and you're entitled to watch whether we actually hold to it — including on the compounds we sell, where the temptation runs the other way.
The measure is simple: do we name the model, every time, including when the answer is unflattering? Hold us to it.
Opinions are the publication's own. The Assay is published by Merit Sciences. Research use only; nothing here is medical advice.
For research use only · Not for human or veterinary use · No compound discussed here is FDA-approved for any indication